ICE is a chemotherapy combination made up of three drugs: ifosfamide, carboplatin, and etoposide. The acronym comes from the first letter of each drug name. It is primarily used as a salvage regimen for lymphomas that have come back after initial treatment or stopped responding to it, and it often serves as a bridge to stem cell transplant.
The Three Drugs and How They Work
Each drug in the ICE combination attacks cancer cells through a different mechanism, which is why they’re used together. Ifosfamide is an alkylating agent, meaning it damages cancer cell DNA directly by creating chemical bonds that prevent the DNA strands from separating and replicating. Carboplatin is a platinum-based drug that works similarly, binding to DNA and disrupting its structure so the cell can’t divide. Etoposide takes a different approach: it blocks an enzyme that cancer cells need to untangle and repair their DNA during division.
By hitting cancer cells at multiple points in the replication process, the three drugs together are more effective than any single agent alone. This combined assault makes it harder for cancer cells to develop resistance to one particular mechanism of action.
Which Cancers ICE Treats
ICE is most commonly used for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma. “Relapsed” means the cancer returned after initially responding to treatment, while “refractory” means the cancer never responded adequately to first-line therapy. In T-cell lymphomas specifically, ICE-based regimens have achieved overall response rates of at least 50%.
For relapsed Hodgkin lymphoma, ICE alone produces complete remission in roughly 32% of patients. Newer approaches that combine ICE with immunotherapy drugs have pushed that number higher, with one trial showing complete remission rates of about 62% when an immune checkpoint inhibitor was added to the regimen.
The primary goal of ICE in many cases is not to cure the lymphoma on its own but to shrink it enough that the patient becomes eligible for an autologous stem cell transplant. The transplant itself is what offers the best shot at long-term remission. ICE also helps mobilize stem cells from the bone marrow into the bloodstream, where they can be collected and stored before the transplant procedure.
What a Treatment Cycle Looks Like
A typical ICE cycle runs over two to three days and is repeated roughly every two to three weeks. Most patients receive two or three cycles total. The exact timing between cycles depends on how quickly blood counts recover. In clinical trials, the median gap between cycles has been about 20 to 21 days, though the regimen can technically be repeated as soon as 14 days after the previous cycle if blood counts bounce back fast enough.
ICE has traditionally been given as an inpatient regimen, meaning you stay in the hospital for the duration of each cycle. This is partly because ifosfamide requires heavy hydration and a protective medication to prevent bladder damage, and that’s easier to manage in a hospital setting. However, some cancer centers have adapted ICE for outpatient delivery by splitting the ifosfamide dose across three days instead of concentrating it. Research has confirmed that this fractionated outpatient approach is both effective and well-tolerated.
On treatment days, you’ll receive the drugs through an IV. Carboplatin is typically given on the first day, while ifosfamide and etoposide are spread across the treatment window. The infusions can run for several hours. Ifosfamide, in particular, may be given as a continuous 12-hour drip.
The Role of Mesna
One important detail about ICE is that ifosfamide produces a byproduct in the body that can severely irritate the bladder lining, a condition called hemorrhagic cystitis. To prevent this, a protective drug called mesna is always given alongside ifosfamide. Mesna binds to the toxic byproduct in the urinary tract and neutralizes it before it can cause damage.
Mesna is often mixed directly into the same IV bag as ifosfamide so the two are delivered simultaneously. An additional dose of mesna continues after the ifosfamide infusion ends, either through an IV over several hours or as oral tablets taken at timed intervals. This extended dosing ensures the bladder stays protected as the body processes the last of the ifosfamide.
Side Effects and Recovery
The most significant side effect of ICE is suppression of blood cell production. White blood cell counts, red blood cell counts, and platelet counts all drop substantially after each cycle. This is expected and temporary, but it creates a window of vulnerability. Low white blood cells raise the risk of serious infections, low platelets increase bleeding risk, and low red blood cells cause fatigue and anemia. Blood counts are monitored closely between cycles, and treatment doesn’t proceed until they’ve recovered to safe levels.
Growth factor injections are commonly given after each cycle to speed up white blood cell recovery. Platelet and red blood cell transfusions may be needed if counts drop dangerously low. Most patients experience the lowest blood counts about 7 to 14 days after treatment, with recovery in the days that follow.
Beyond blood counts, common side effects include nausea and vomiting (managed with anti-nausea medications given before and during treatment), fatigue that can be significant, hair loss, and loss of appetite. Ifosfamide can occasionally cause confusion or drowsiness due to its effects on the nervous system, a side effect called encephalopathy. Kidney function is also monitored because both ifosfamide and carboplatin can stress the kidneys, which is another reason heavy IV fluids are part of the protocol.
What Happens After ICE
If ICE successfully reduces the lymphoma, the next step for most patients is an autologous stem cell transplant. Before the transplant, stem cells are collected from your bloodstream through a process called apheresis, which is similar to a blood donation. The ICE cycles themselves help push stem cells out of the bone marrow and into circulation, making collection easier.
After collection, you receive high-dose chemotherapy designed to wipe out remaining cancer cells, followed by reinfusion of your stored stem cells to rebuild the bone marrow. The ICE phase typically takes six to nine weeks from start to finish, depending on how many cycles are needed and how quickly you recover between them. The transplant process adds additional weeks of hospitalization and recovery afterward.
For patients who aren’t transplant candidates, ICE can still be used as a standalone salvage regimen to control the disease and reduce symptoms, though the long-term outlook is generally better when transplant is part of the plan.